Singapore will gradually integrate more traditional Chinese medicine treatments into its public healthcare system to explore how such therapies could complement Western ones. https://t.co/wSufeObJeZ ...

Regencell Bioscience Holdings Ltd. RGC, a Hong Kong-based biotech startup with no reported revenue, has gained more than 59,000% in 2025. The company, which claims to be developing traditional Chinese herbal treatments for childhood ADHD and autism, saw its market value reach nearly $30 billion, by Monday's close. Following a 38-for-1 stock split announced earlier in June, the stock skyrocketed by over 280% on Monday.Read Next: Sunrun, First Solar Plunge—Solar Stocks Hit Hard By Trump Tax Bill: Latest Regen ...

Regencell CEO Yat-Gai Au controls 86.24% of the total number of shares outstanding, according to FactSet data.The company's year to date performance is off the charts too, having risen 46,000% in 2025. By Monday's close, Regencell, founded in 2014 and traded on Nasdaq under the ticker 'RGC' since 2021, had a total market capitalization of $29.7 billion, according to S&P Capital IQ.Shares of Regencell, which says it develops traditional Chinese herb treatments to treat childhood attention deficit hyperactivi ...